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Abstract Intra-abdominal infection (IAI) is a complex disease entity in which dif-
ferent aspects must be balanced in order to select the proper antimicrobial
regimen and determine duration of therapy. A current classification indicates
different faces of peritonitis. Primary peritonitis implies an intact gastro-
intestinal tract without overt barrier disruption. Secondary peritonitis refers
to localized or diffuse peritoneal inflammation and abscess formation due to
disruption of the anatomical barrier. Tertiary peritonitis includes cases that
cannot be solved by a single or even sequential surgical intervention, often in
combination with sequential courses of antimicrobial therapy. The most
frequently used classification distinguishes ‘uncomplicated’ and ‘compli-
cated’ IAI. In uncomplicated IAI, the infectious process is contained within a
single organ, without anatomical disruption. In complicated IAI, disease is
extended, with either localized or generalized peritonitis. However, there ex-
ists more than a single dimension of complexity in IAI, including severity of
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disease expression through systemic inflammation. As the currently used
classifications of IAI often incite confusion by mixing elements of anatomical
barrier disruption, severity of disease expression and (the likelihood of) re-
sistance involvement, we propose an alternative for the current widely ac-
cepted classification. We suggest abandoning the terms ‘uncomplicated’ and
‘complicated’ IAI, as they merely confuse the issue. Furthermore, the term
‘tertiary peritonitis’ should likewise be discarded, as this simply refers to
treatment failure of secondary peritonitis resulting in a state of persistent
infection and/or inflammation. Hence, anatomical disruption and disease
severity should be separated into different phenotypes for the same disease in
combination with either presence or absence of risk factors for involvement
of pathogens that are not routinely covered in first-line antimicrobial regi-
mens (Pseudomonas aeruginosa, enterococci, Candida species and resistant
pathogens). Generally, these risk factors can be brought back to recent ex-
posure to antimicrobial agents and substantial length of stay in healthcare
settings (5–7 days). As such, we developed a grid based on the different
components of the classification: (i) anatomical disruption; (ii) severity of
disease expression; and (iii) either community-acquired/early-onset health-
care-associated origin or healthcare-associated origin and/or recent anti-
microbial exposure. The grid allows physicians to define the index case of IAI
in a more unequivocal way and to select the most convenient empirical
antimicrobial regimens. The grid advises on the necessity of covering noso-
comial Gram-negative bacteria (including P. aeruginosa), enterococci and
yeasts. The basis of antimicrobial therapy for IAI is that both Gram-negative
and anaerobic bacteria should always be covered.
In recent years, some newer agents such as doripenem, moxifloxacin and
tigecycline have been added to the antimicrobial armamentarium for IAI. For
patients in whom the source can be adequately controlled, antimicrobial
therapy should be restricted to a short course (e.g. 3–7 days in peritonitis).
1. Introduction
Intra-abdominal infections (IAI) represent a
particular clinical challenge, as they differ from
other types of infections in a number of aspects.[1]
The clinical spectrum of IAI is very broad, ranging
from uncomplicated acute appendicitis to gen-
eralized peritonitis caused by a perforated ischaemic
bowel. Surgery – often referred to as surgical
source control – is essential and generally con-
sidered to be a decisive factor for the outcome in
patients with IAI.[2-4] Source control is defined as
the elimination of the source of infection and the
control over ongoing contamination. This concept
is based on the following principles: drainage of
abscesses or contaminated fluid, debridement of
necrotic tissue, and restoration of anatomy and
function.[5] In addition, during surgery for gas-
trointestinal pathology, excision of diseased viscus,
if feasible, and gastrointestinal diversion, if ap-
plicable, may limit the risk of anastomotic leak-
age and subsequent peritonitis. Source control
may be achieved through laparotomy, laparos-
copy and percutaneous drainage (ultrasound or
CT guided). In the absence of perforation, opera-
tive intervention is generally not indicated.
The microbial aetiology and microbiological
diagnosis pose another challenge. As the gastro-
intestinal tract contains a huge number of different
micro-organisms, IAI is usually polymicrobial.
Yet, not all bacteria can be isolated by means of
routine cultures.[6] On the other hand, not all bac-
teria isolated represent true pathogens, as most
enteric bacteria are of relatively low virulence.
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The profile of the patient determines the ap-
proach for IAI. Community-acquired IAI may be
more rapidly diagnosed than that occurring in
critically ill patients in whom signs and symptoms
may be masked by other inflammatory processes.
Critically ill patients also have more pronounced
risk profiles, as IAI is more often associated with
acute kidney injury and septic shock.[7] Further-
more, a healthcare origin of infection is important
as there exists a higher likelihood of involvement
of resistant pathogens with the potential for in-
appropriate empiric antimicrobial therapy and
detrimental outcomes. In the present review,
emphasis is given to empirical choices of anti-
microbial therapy in patients with IAI. Special
attention is given to the different elements that
should be taken into account in order to select the
proper regimen. Issues such as new agents and
duration of therapy are mentioned briefly.
2. The Challenge of Definitions
2.1 Primary, Secondary and Tertiary
Peritonitis/Complicated vs Non-Complicated
Intra-Abdominal Infection (IAI)
Primary peritonitis includes distinct disease en-
tities such as peritonitis in decompensated liver cir-
rhosis and peritonitis in nephrotic syndrome with
ascites (e.g. with Streptococcus pneumoniae). These
imply an intact gastrointestinal tract without overt
barrier disruption. Secondary peritonitis refers to
localized or generalized peritoneal inflammation
and abscess formation due to disruption of the
anatomical barrier (e.g. perforated appendicitis or
diverticulitis). In the literature, so-called ‘tertiary
peritonitis’ has been defined, referring to cases that
cannot be solved by a single or even sequential
surgical intervention, in combination with often
sequential courses of antimicrobial therapy, either
with or without antifungal coverage.[8] A suggested
approach for these difficult-to-solve cases consisted
of an open-abdomen treatment associated with
chronic serositis and colonisation with often re-
sistant pathogens. This definition refers to treat-
ment failure in secondary peritonitis.
The most frequently used classification for IAI
in randomized controlled trials of antimicrobial
regimens distinguishes between ‘uncomplicated’
and ‘complicated’ IAI.[9] In uncomplicated IAI,
the infectious process is contained within a single
organ, without anatomical disruption. In most
patients, these infections can be managed with
surgical resection alone and, with the exception
of peri-operative prophylaxis, no additional anti-
microbial therapy is necessary. Acute appendicitis
and cholecystitis are common examples of un-
complicated IAI.
In ‘complicated’ IAI, disease is extended with
either localized or generalized peritonitis. These
cases require a more prolonged course of anti-
microbials following the surgical procedure.
In clinical trials, essentially only IAI with un-
eventful clinical courses are selected. Infections
are categorized as complicated on the basis of the
sole criterion of anatomical barrier disruption,
and selected on the basis of often rigid inclusion
and exclusion criteria for cases with mild to
moderate disease severity. However, IAI com-
prises more than a single dimension of complex-
ity. In the mind of clinicians, ‘complicated’ may
refer to severity of disease expression, anatomical
extent of the infectious process and the involve-
ment of resistant pathogens. Hence, the literature
has been contaminated with this bias.
2.2 An Alternative Categorization of IAI
As the current classifications of IAI often in-
cite confusion by mixing elements of anatomical
barrier disruption, severity of disease expression
and (the likelihood of) resistance involvement, we
propose an alternative. We suggest abandoning
the terms ‘uncomplicated’ and ‘complicated’ IAI,
as they merely confuse the issue. Furthermore,
the term ‘tertiary peritonitis’ should likewise be
discarded, as this simply refers to treatment fail-
ure of secondary peritonitis resulting in a state of
persistent infection and/or inflammation. Hence,
anatomical disruption and disease severity should
be separated into different phenotypes for the
same disease (e. g. diverticulitis); this should then
be combined with either presence or absence of
risk factors for involvement of pathogens that are
not routinely covered in first-line antimicrobial
regimens (Pseudomonas aeruginosa, enterococci,
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Candida species and resistant pathogens). Generally,
these risk factors can be reduced to recent exposure
to antimicrobial agents and substantial length of
stay in healthcare settings (5–7 days). As such,
we developed a grid based on the different com-
ponents in the classification: (i) anatomical dis-
ruption; (ii) severity of disease expression; and
(iii) either community-acquired/early-onset health-
care-associated origin or late-onset healthcare-
associated origin and/or recent antimicrobial
exposure (table I).
The grid allows physicians to define the index
case of IAI in a more unequivocal way and sub-
sequently to select the most convenient empirical
antimicrobial regimen (table II). As IAI basically
always requires coverage against Gram-positive,
Gram-negative and anaerobic bacteria, the grid
more precisely advises on the necessity of cover-
ing nosocomial Gram-negative bacteria (including
P. aeruginosa), enterococci, yeasts and resistant
pathogens. The necessity of additionally covering
these pathogens is based on the assessment of
overall risk of treatment failure (according to the
three components of the IAI classification). For
example, the grid advises a baseline regimen for
community-acquired IAI presenting with loca-
lized peritonitis and severe sepsis. However,
should the patient present with either diffuse
peritonitis and/or septic shock, the grid advises to
additionally cover nosocomial Gram-negative
bacteria and enterococci. This is because it is
perceived as a grim clinical situation (more diffi-
cult surgical cleaning and/or presence of organ fail-
ure) in which the negative consequences of in-
appropriate antimicrobial therapy are close to
inevitable. However, from a purely microbiological
viewpoint, there is little to support this approach.
The antimicrobial options provided by the grid
are mainly based on clarity and simplicity, albeit
however, that local epidemiology should always
be considered as well (see section 3.2.1). The grid
does not include the additional dimension of
treatment failure. As such, it reflects the initial
conditions of IAI presentation, similar to a severity
of disease scoring system used as a prognostic
indicator such as the APACHE II (Acute Phys-
iology and Chronic Health Evaluation II) score
reflecting the first 24 hours of disease presenta-
tion.[10] However, throughout this paper, we use
the definitions used in individual publications.
3. Antimicrobial Therapy
3.1 General Considerations
The main objectives of antimicrobial therapy
in the treatment of IAIs are to prevent local and
haematogenous spread, and to reduce late com-
plications. As for other infections, early admin-
istration of antibacterials is important, and it is
logical that these are administered upon the diag-
nosis of complicated IAI. When preoperative
imaging is unequivocal, treatment should not be
delayed for intraoperative confirmation. Perio-
perative prophylaxis should not be used as an
alternative or temporizing strategy in these patients:
for patients with suspected IAI but equivocal
findings who undergo explorative laparotomy,
we advise the administration of antibacterials
even without confirmation of IAI; when clinical
syndrome and preoperative imaging are highly
suggestive, treatment should not be delayed for
intra-operative confirmation. This is a setting of
early empirical treatment requiring high sensi-
tivity for the diagnosis of complicated IAI at a
certain cost for specificity, and not a setting of
peri-operative prophylaxis. In critically ill patients,
the threshold for starting antibacterials may be
even lower, as the delayed treatment of infections
is associated with considerable morbidity and








Community-acquired or early-onset healthcare-associated IAI
<7 days after hospital admission)
Without perforation 1 1 2
Localized peritonitis 1 1 2
Diffuse peritonitis 1 2 2
Late-onset healthcare-associated IAI (‡7 days after hospital
admission) and/or recent antimicrobial exposure
Without perforation 2 2 2
Localized peritonitis 2 2 3
Diffuse peritonitis 2 3 3
IAI = intra-abdominal infection.
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mortality. Upon documentation of intra-abdominal
pathology without infection, antibacterials should
be discontinued.
Intravenous administration is the only route for
early antimicrobial treatment in truly complicated
IAI. Oral administration is to be avoided at that
stage, as absorption will usually be unreliable, and
the effect may be delayed. Postoperatively, oral
administration may be considered with improve-
ment of clinical condition and recovery of gastro-
intestinal function.
3.2 Factors to Take into Account when
Selecting Empirical Antimicrobial Therapy
for IAI
IAI are typically polymicrobial, and require
empirical coverage for Gram-positive and Gram-
negative, aerobic and anaerobic bacteria, with
the latter most relevant for infections originating
from the lower gastrointestinal tract (distal small
bowel to rectum). Whether, in addition, coverage
must be given for enterococci, P. aeruginosa,
Candida species and resistant pathogens, such as
extended-spectrum b-lactamase (ESBL)-producing
Enterobacteriaceae, depends on microbiological
issues, epidemiological patterns and patient-
related factors.
3.2.1 Microbiological Considerations
The microbiology of IAI reflects a summary of
transient or persistent normal gastrointestinal flora
with potentially pathogenic micro-organisms.
As such, the aetiology of IAI includes Gram-
positive, Gram-negative and anaerobe bacteria as
well as fungal species. However, about 20–25% of
cultures in secondary peritonitis prove nega-
tive.[11] In another quarter of the patients, the
infection is monomicrobial and, in half of the
patients peritonitis is polymicrobial.[12] However,
the precise mix of pathogens involved is highly
variable depending on several factors that lead to
the risk profile of the patient. Table III gives an
overview of the most common causative patho-
gens in IAI. Interpretation of the extent of micro-
organisms involved is hampered by the limited
microbiological workup of anaerobe cultures
in general practice. In principle, IAI are poly-
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local/systemic inflammation) and an anaerobic
component (responsible for abscess formation).
The value of microbiological identification is a
matter of debate, as cultures often reveal mixed
flora in which it is difficult to distinguish con-
taminants from true pathogens. In cases of com-
munity-acquired IAI with secondary peritonitis,
cultures rarely influence the management of the
patient as the encountered flora is generally sus-
ceptible to the standard regimens.[15] In cases of
healthcare-associated IAI, peri-operative cultur-
ing is routinely indicated, as responsible patho-
gens are less predictable and more likely resistant
to first-line or standard empirical regimens
(amoxicillin/clavulanic acid or combination of
cefuroxim plus a 5-nitroimidazole). In addition,
peri-operative cultures may reveal other patho-
gens such as enterococci, P. aeruginosa or yeast,
which are also not routinely covered by first-line
antimicrobial regimens.As such, culture results allow
for either correction of an initially inappropriate
choice or de-escalation. However, irrespective of
the isolated pathogens, coverage against Gram-
positive, Gram-negative and anaerobic bacteria
remains indicated. Besides adapting the empiri-
cally initiated antimicrobial therapy, culture re-
sults provide insights into local epidemiological
patterns, which can be valuable in selecting the
proper agents in the empirical phase.
Blood cultures are generally not recommended
as they usually do not provide additional valuable
information, especially in community-acquired
cases. However, in cases with severe sepsis or
septic shock, its use is mandatory.[16] Also, blood
cultures positive for anaerobic bacteria, especially
Bacteroides fragilis, in sepsis of unclear origin, are
a strong indication of an intra-abdominal focus.[17]
Systemic breakthrough as evidenced by positive
blood culture represents fulminant infection,
with a particularly grim prognosis.[18]
Location of Primary Source and Microbiology
Location of the primary source of secondary
peritonitis influences the spectrum of pathogens
involved, as stomach, upper small bowel, lower
small bowel and large bowel have a distinct flora
in terms of microbial species and density. Figure 1
summarizes initial culture results, according
to the primary source of the IAI as found by
de Ruiter et al.[19] There exists a preponderance
of Gram-negative and anaerobic bacteria in IAI
originating from colorectal sources or appendicitis.
In gastro-duodenal perforation, Gram-positive
bacteria and yeasts are isolated most frequently.
Table III. Frequently isolated pathogens in complicated intra-abdominal infections
Micro-organism Clinically relevant resistance problem
Gram-negative bacteria
Enterobacteriaceae (Escherichia coli, Enterobacter
spp., Klebsiella spp., Proteus spp., etc. )
ESBL-producing strains likely in healthcare-associated infection. In E. coli
fluoroquinolone-resistance may be up to 20% in some geographic areas
Non-fermenting Gram-negative bacteria (Pseudomonas
aeruginosa, Acinetobacter baumannii, etc.)
Multidrug resistance most likely in healthcare-associated infection
Gram-positive bacteria
Streptococci No clinically relevant resistance problem.
Enterococci Problems of resistance likely in healthcare-associated infections, especially
when caused by Enterococcus faecium.[13] Ampicillin-resistance and associated
production of b-lactamases is a concern in some geographic areas, as is
glycopeptide resistance
Coagulase-negative Staphylococci Methicillin resistance most likely in healthcare-associated infection. Clinical
pathogenecity uncertain
Staphylococcus aureus Methicillin resistance possible in healthcare-associated infection
Anaerobic bacteria (Bacteroides fragilis,
Clostridium spp., etc)
Important resistance against clindamycin and cefoxitin in certain geographic
areas. Resistance against metronidazole is rare[14]
Candida spp. Selection towards non-albicans Candida spp. with reduced susceptibility to
fluconazole in patients with prior exposure to this agent in hospitalized patients
ESBL =extended-spectrum b-lactamase.
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In IAI from a small intestine source, there is a
relative balance between the four different groups
of pathogenic micro-organisms. However, in sub-
sequentweeks there is a shift in culture results, show-
ing an increase in Gram-positive bacteria, while the
prevalence of Gram-negatives decreases.[19]
Healthcare-Associated vs Community-Acquired IAI
Healthcare-associated infection includes all
circumstances in which patients have had close
association with either acute or chronic care
settings.[20] The relevance of the issue is that
healthcare-associated IAI is inherently associated
with an increased risk of resistant pathogen
involvement. Based on a 10-year single-centre
study of over 2000 cases of complicated IAI,
Swenson et al.[21] found that resistant pathogens
were isolated from 79% of healthcare-associated
infections. The risk of involvement of resistant
pathogens is, however, also the result of exposure
to antibacterials, irrespective of having close as-
sociation with healthcare facilities as mentioned
in the definitions.[20] However, it should be men-
tioned that, in IAI occurring within the first days
of hospitalization, the prevalence of resistant
pathogens is not dramatically increased.[21,22] In
Swenson et al.,[21] the average time between hospital
admission and treatment of resistant pathogens
was 10 days (13 days for non-fermenting Gram-
negatives, 8 days for resistant staphylococci,
23 days for vancomycin-resistant enterococci
[VRE] and 7 days for fungi). Also important, the
average time from admission to treatment of non-
resistant pathogens was still 5 days. Assuming
that in these cases resistant pathogens were also
cultured after about 5–7 days, these data indicate
a timeframe within which resistant pathogens do
not necessarily need to be covered in the empirical
regimen. Of course, local epidemiological pat-
terns should always be taken into account (e.g.
quinolone resistance in Escherichia coli in the
community). In nosocomial pneumonia, the risk
of resistant pathogen involvement is also sub-
stantial after a hospitalization of about 5–7 days,
leading to the concept of early-onset and late-
onset infection.[23] In IAI, however, such a con-
cept, although probably of value in the context of
empirical choices within antimicrobials, is not
proposed in the current guidelines, in which no
difference is made in risk assessment of health-
care-associated IAI according to length of hos-
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Fig. 1. Initial culture results in secondary and tertiary peritonitis: percentages of positive cultures according to the primary source of
infection.[19]
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distinction is made between community-acquired
or early-onset healthcare-associated IAI (<5–7
days) and late-onset healthcare-associated IAI.
Yet, recent exposure to antimicrobial agents must
be considered as a risk factor for resistance, irre-
spective of origin of onset. Therefore, when it
comes to selecting an empirical antimicrobial reg-
imen, cases with community-onset IAI with re-
cent antimicrobial exposure (‡2 days of therapy)
are categorized together with late-onset health-
care-associated IAI.
Local Epidemiology of Resistance
Empirical choices of antimicrobial agents are
based upon the risk assessment of involvement of
resistant pathogens. In IAI literature, the concept
of resistance goes beyond in vitro multidrug
resistance and basically includes all pathogens
not essentially covered by first-line empirical reg-
imens. As such, the following micro-organisms
are considered ‘resistant’: methicillin-resistant
Staphylococcus aureus (MRSA), coagulase-negative
staphylococci, VRE, ESBL-producing Entero-
bacteriaceae, quinolone-resistant E. coli, non-
fermenting Gram-negative bacteria (including
P. aeruginosa, Stenotrophomonas maltophilia,
Acinetobacter baumannii) and yeasts.
Although the ongoing emergence of resistance
is a global concern, it is local epidemiology data
that should be taken into account as they can
substantially differ from the national average.[25]
For example, in a general hospital in Houston
(TX, USA), the prevalence of fluoroquinolone-
resistant E. coli was 2- to 4-fold higher than the
national averages.[25] The increase of quinolone-
resistant E. coli in community-acquired infec-
tions was mostly a matter of urinary isolates in
male outpatients or in sputum samples from in-
patients. Therefore, the extent to which this pro-
blem weighs on the specific aetiology of IAIs is
uncertain. Large multicentre surveillance studies
which focus on resistance are scarce in IAI and
hence the true prevalence of resistance is hard
to estimate. Regardless, it is unjustified to take
national averages of ‘clinical specimens’ as a ref-
erence for aetiology in IAIs. Data from the
European Antimicrobial Resistance Surveillance
System indicate that, in France, about 22% of all
clinical isolates of S. aureus tested (n = 4720) were
resistant to methicillin.[26] In contrast, in a pro-
spective study performed in 25 French centres,
Montravers et al.[27] found not a single S. aureus
isolate from nosocomial IAI to be methicillin
resistant. So, although obviously present in other
types of infection, MRSA is not a common patho-
gen in secondary peritonitis. An identical observa-
tion can be made for VRE. Although enterococci
are important pathogens in IAI, as the overall
prevalence of VRE is low, the role of VRE is
limited to exceptional cases with late disease and
to risk groups such as complicated liver trans-
plantation.[22,27-29] As such, in the majority of
IAI, including community-acquired and early
secondary peritonitis, enterococci and, in partic-
ular circumstances, VRE, do not need to be covered
in the empirical regimen.
The need to cover ESBL Enterobacteriaceae in
community-acquired IAI is also strongly dependent
on geographic ecology. There are clear signals of
epidemiological indications of expansion of
ESBL E. coli and Klebsiella species in the com-
munity. This may be provoked by excessive use of
antimicrobials in medical practice but also by the
widespread contamination of the food chain with
ESBL Enterobacteriaceae, which is also the case
in countries with – until now – no extreme resis-
tance problems, such as Denmark.[30-32] Data
from India indicate that more than half of all
E. coli strains and about one-third of Klebsiella
strains isolated from IAI produce ESBL.[33] Data
from Hawser et al.[33] show important differences
in resistance rates for E. coli and Klebsiella spe-
cies among European countries, albeit that the
study is unclear about the origin of infection
(either community or hospital onset). Resistance
rates for E. coli were highest in Turkey, Greece
and Portugal, while fewer resistance problems
were noted in France, Lithuania and Estonia. For
Klebsiella, carbapemens appear to be a good choice
for all European countries (more than 90% sus-
ceptibility), with the exception of Greece, where
only 43% of isolates were susceptible for both
imipenem and ertapenem. In particular, because
of the huge geographic variation in resistance
rates, special attention should be given to patients
with a recent history of travelling in regions
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known to have particular resistance problems,
such as India, Thailand or Egypt.[34,35] However,
the extent to which antibacterial resistance in
Enterobacteriaceae results in worse clinical out-
comes in cases of community-acquired IAI, espe-
cially in circumstances where adequate surgical
source control was promptly achieved, remains
unknown.
Finally, P. aeruginosa is also a feared patho-
gen, the importance of which is frequently over-
estimated in the context of IAI. P. aeruginosa is a
typically opportunistic pathogen, generally affect-
ing immunocompromized or otherwise severely
debilitated patients. Given the relatively poor
ability of this micro-organism to invade tissue,
the isolation of P. aeruginosa often represents
contamination rather than true pathogen, espe-
cially in cases in which surgical intervention was
promptly performed and infection, as such, was
not established. In the large study by Swenson
et al.,[21] non-fermenting Gram-negative bacteria
(P. aeruginosa, S. maltophilia and A. baumannii)
accounted for fewer than 6% of all IAIs. In a series
of secondary peritonitis, P. aeruginosa accounted
for about 9% of infections. Edelsberg et al.[36]
demonstrated that, in both community-acquired
and healthcare-associated IAI, coverage of Pseudo-
monas did not add to higher rates of clinical suc-
cess, indicating the limited importance of these
pathogens. Yet, in patients with a particular risk
profile for opportunistic pathogens (e.g. immuno-
compromized patients), coverage of Pseudomonas
is warranted in all cases.[37]
Coverage Against Enterococci
Enterococcal involvement in IAI is generally
encountered in patients with a loaded medical
history and is associated with a grim prog-
nosis.[38-40] Routine coverage against enterococci
is not mandatory in community-acquired IAI as
it appears not to give additional benefit.[41-43]
Empirical coverage of enterococci is warranted in
nosocomial IAI, which, in the majority, represents
cases in whom early surgical source control was
not achieved or complications such as anasto-
motic leakage occur. Reasonable indications for
enterococcal coverage include septic shock, pro-
longed treatment with cephalosporins, immuno-
suppression, presence of prosthetic heart valves
and recurrent IAI with associated severe sepsis.[44-47]
When enterococcal infections are suspected, cover-
age should be included in the empirical regimen.
Empirical therapy should primarily target Entero-
coccus faecalis.[24] This may require additional
drugs such as ampicillin or vancomycin when ce-
phalosporin-based regimens are prescribed. In
patients with a very high risk profile (e.g. a liver
transplant patient with an IAI originating from
the hepatobiliary tree or a patient known to be
colonized with VRE) coverage of Enterococcus
faecium is recommended. In this case, tigecycline
or linezolid can be prescribed.[48,49]
Coverage of Methicillin-Resistant Staphylococcus
Aureus (MRSA)
The presence ofMRSAmay either be based on
pre-infection colonization or acquisition in the
hospital. MRSA is often isolated in patients with
long-standing, difficult-to-treat infections such as
tertiary peritonitis. Vancomycin has been used
most extensively in patients with intra-abdominal
MRSA infection, but other drugs with demon-
strated anti-MRSA activity, such as linezolid, ti-
gecycline, daptomycin or quinupristin/dalfopristin,
can be used Clinical experience in this category of
severely ill patients is limited.
Coverage Against Candida Species
With the exception of patients with a particular
risk profile for fungal infections (e.g. neutropenic
patients) or patients with anastomotic leakage,
Candida should not be covered by the empirical
regimen.[50,51] Even when initial culture results
show Candida spp., the clinical relevance of these
isolations remains vague and probably not all
patients need antifungal coverage.[52] In a pro-
spective cohort of 62 patients with peritonitis
following peptic ulcer perforations, Candida was
isolated from 37% of cases (n = 23).[53] Antifungal
therapy was initiated in eight patients, of whom
only three survived. Yet, all patients in whom no
antifungal therapy was initiated survived. This
illustrates the ambiguous role of Candida as a
pathogen in IAI.
An algorithm to determine which patients may
benefit from antifungal therapy has been pro-
posed.[54] This algorithm is based on (i) presence
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or absence of established peritonitis; (ii) isolation
ofCandida spp.; (iii) presence or absence of severe
sepsis or septic shock; and (iv) immunocompromized
status. This algorithm, however, has not yet been
subject to clinical evaluation. Invasive candidia-
sis is nearly always preceded by overt Candida
colonization, and although the positive predictive
value of prior colonization is rather low, failure
to cover Candida species in the empirical phase is
associated with treatment failure and death.[55,56]
Therefore, in cases of overt Candida colonization
prior to infection onset, or when peri-operative
cultures reveal Candida species, antifungal ther-
apy is recommended. Dupont et al.[57] developed
and validated a simple score to estimate the like-
lihood of Candida involvement in peritonitis.
This score describes risk levels ofCandida involve-
ment based on the presence or absence of four
risk factors: female gender, upper gastrointestinal
tract origin of peritonitis, peri-operative cardio-
vascular failure and previous antimicrobial ther-
apy. The risk of Candida involvement is minimal
when no or only one risk factor is present and
maximal when all four are present. In the pre-
sence of three risk factors, the score had 84%
sensitivity, but the 50% specificity was rather
low, thereby limiting its usefulness in clinical
practice.
Previous antibacterial therapy may also result
in selection of fungi. With regard toCandida spp.,
prior exposure to fluconazole may select for non-
albicans Candida spp. with potentially reduced
susceptibility to this agent.[58] In these cases, an
echinocandin is recommended.[59]
3.3 Patient-Related Factors
Recent guidelines for the diagnosis and treat-
ment of complicated IAI make use of the concept
‘high-risk patient’.[24] This concept encompasses
different risk factors for treatment failure and poor
outcome. The prognosis of IAI depends on the
overall quality of the management of infection,
which includes aspects such as timely recognition
of signs and symptoms, physiological resuscita-
tion and organ support, adequate surgical source
control and prompt initiation of appropriate
antimicrobial therapy. Delays in initial interven-
tion and inability to achieve adequate debride-
ment or drainage because of the high degree of
peritoneal contamination are associated with
failure of source control for IAI.[3,4] Besides as-
pects of infection management, patient-related
factors can also compromise the odds of survival.
Table IV summarizes conditions leading to an
increased risk of inadequate management and
subsequent death. A distinction has to be made
between underlying conditions and acute condi-
tions, or severity of disease expression.
3.3.1 Underlying Co-Morbidities
Older age, low albumin level and poor nutri-
tional status are risk factors for death following
failure of source control.[11,21,24,60-62] Yet, relation-
ships between particular underlying conditions,
involvement of resistant pathogens, inappropriate
antimicrobial therapy and subsequent death have
not been demonstrated so far. According to a
large single-centre study including 2049 patients,
complicated IAIs caused by multidrug-resistant
pathogens are associated with higher mortality
rates (17.0% vs 8.6%; odds ratio 2.19, 95% CI
1.53, 3.13).[21] Underlying conditions associated
with the involvement of resistant pathogens were
current corticosteroid use, solid organ transplant,
and pulmonary and liver disease. However, these
findings were not adjusted for previous anti-
microbial exposure, the major risk factor for




Older age (>70 years) Diminished inflammatory response
implying a risk of delayed recognition of
signs and symptoms with delayed








Higher risk of involvement of multidrug-
resistant pathogens and/or yeasts
Acute conditions
High degree of intra-
abdominal contamination
Difficult source control; inability to
completely clean the peritoneal cavity
Severe sepsis/septic
shock
Increased distribution volume and
renal clearance, implying a risk of
insufficient dosing of antimicrobial
agents with inadequatemicrobial killing
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resistance. To the best of our knowledge, no un-
derlying condition (as such HIV, chronic ob-
structive pulmonary disease, etc.) constitutes an
increased risk of involvement of resistant patho-
gens. Therefore, the decision to cover resistant
pathogens should essentially be based on the
presence of major risk factors as indicated in the
grid: recent antimicrobial exposure and/or late-
onset healthcare-associated IAI.
3.3.2 Penicillin Allergy
Patients with proven allergy to penicillin should
not receive ampicillin or its derivates such as
amoxicillin or piperacillin/tazobactam. In cases
of non-IgE-mediated allergy, cross-allergy is un-
common with cephalosporins and carbapenems,
and never observed with fluoroquinolones, amino-
glycosides, glycopeptides, imidazoles and linezolid.
If the proposed regimen includes a penicillin de-
rivate, it is better replaced by a cephalosporin or
carbapenem. One should take into account,
however, that cephalosporins have no activity
against enterococci and anaerobic Gram-negative
bacteria and that ertapenem does not cover
Pseudomonas species. When indicated, a glyco-
peptide for enterococci or an imidazole for
anaerobic bacteria must be prescribed. In IgE-
mediated allergy, cross-reaction with cephalo-
sporins is rare. Nevertheless, these agents should
be avoided. The drug of choice in such cases is
aztreonam (combined with a glycopeptide and, if
necessary, an imidazole) or a fluoroquinolone
(combined with an imidazole if considered necess-
ary).[63,64] Tigecycline is another valuable option in
penicillin-allergic patients.[65] Additional coverage
ofP. aeruginosa is, however, necessary in patients at
risk for Pseudomonas involvement.
3.3.3 Severity of Disease Expression
Severity of disease expression refers to the
systemic inflammatory reaction provoked by
the IAI and associated organ derangements. The
proposed grid differentiates between mild, mod-
erate and severe disease expression. Basically, this
correlates with the traditional sepsis classifica-
tion, respectively, sepsis, severe sepsis and septic
shock.[66] Hereby, sepsis is a condition characterized
by a systemic inflammatory response syndrome,
severe sepsis is accompanied by additional organ
failure, and septic shock refers to a condition
associated with arterial hypotension. The habit is
to prescribe more last-line agents (typically car-
bapenems) in more pronounced disease expres-
sion, albeit that there is little rationale to support
this practice. There is no reason to assume re-
sistant pathogens on the basis of disease expres-
sion. As such, in the absence of true risk factors
for resistance (late-onset healthcare-associated
IAI and recent antimicrobial exposure), last-line
antimicrobial agents cannot be recommended.
However, one can assume that, in patients with
moderate to severe disease expression, the margin
by which one can afford inappropriate therapy is
much smaller than in patients presenting with
mild disease. It seems logical that the clinical con-
sequences of inappropriate therapy will be more
serious in patients with septic shock.
Using these elements to consider in selecting
empirical antimicrobial therapy, a list of regimens
is proposed by us. Each of these regimens falls
back on the classification of IAI based on severity
of disease expression (mild, moderate, severe),
anatomical disruption, and community-acquired
or early-onset healthcare-associated origin versus
late-onset healthcare-associated origin and/or re-
cent antimicrobial exposure (2–4 days of therapy)
[table II]. Essentially, three regimens are proposed:
(i) a baseline regimen without coverage of noso-
comial Gram-negatives (including P. aeruginosa),
enterococci orCandida species; (ii) a regimen with
additional coverage of nosocomial Gram-negatives
and enterococci; and (iii) a regimen with coverage
of nosocomial Gram-negatives, enterococci or
Candida species.
The proposed regimens are partially derived
from the guidelines for the diagnosis and manage-
ment of complicated IAIs and the guidelines for the
treatment of invasive candidiasis.[24,59] One should
realize, however, that baseline regimens often cover
a broader spectrum of pathogens than strictly need-
ed (e.g. ertapenem, tigecycline or moxifloxacin).
Yet, in order not to endanger the chances of ap-
propriate therapy, antibacterial restriction should
rather be achieved through correct indications
for antimicrobial therapy and avoidance of un-
necessarily long duration of therapy.
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4. Recently Introduced Agents
Recently, a number of newer drugs in different
classes have been evaluated in the treatment of
complicated IAI. These further expand the ther-
apeutic options and further simplify treatment by
reducing the number of administrations per day.
4.1 Doripenem
Doripenem is the newest carbapenem with a
spectrum similar to that of meropenem and was
approved by the US FDA for the treatment of
complicated IAI in 2007. In a large randomized
controlled trial, it was found to be non-inferior
to meropenem.[67] Compared with imipenem/
cilastatin,[68] doripenem has been reported to
have increased activity to a number of Gram-
negative bacteria and also emergence of resis-
tance during treatment was found to be lower,
but the clinical impact of these findings is unclear.
Doripenem dose in the complicated IAI studies
was 500mg three times daily. Following its ac-
tivity against Pseudomonas and ESBL-producing
Enterobacteriaceae, doripenem is useful when
these pathogens are a concern (table II).
4.2 Moxifloxacin
Moxifloxacin is a broad-spectrum fluoro-
quinolone that has recently been positioned as
first-line agent in the treatment of IAI. It pene-
trates well and accumulates in gastrointestinal
tissues and peritoneal fluid,[69] and has demon-
strated in vitro activity against the majority of
organisms involved in complicated IAIs.[70] It has
been compared with several comparators, in-
cluding b-lactam/lactamase inhibitors, cephalos-
porin-based therapy and carbapenems.[71-73] In
all these studies, non-inferiority with the com-
parator was found. Although an increase in resis-
tance to moxifloxacin has been described in
selected patients, this seems to be variable enough
not to affect clinical efficacy. Yet it is prudent to
evaluate the local resistance patterns when se-
lecting empirical therapy for complicated IAI.
Moxifloxacin is dosed at 400mg once daily.
Moxifloxacin is best positioned as first-line single-
agent therapy in circumstances where fluoro-
quinolone-resistance of E. coli is not an issue
(table II).
4.3 Tigecycline
Tigecycline belongs to a newer class of anti-
bacterials, the glycylcyclines, and had in vitro
activity against the flora commonly isolated
in community-acquired complicated IAI.[74] Its
spectrum does not include Pseudomonas and
therefore this drug is preferably positioned as
first-line single-agent therapy (table II). On the
other hand, tigecycline is active against MRSA,
which can be advantageous in areas with a high
prevalence of MRSA. The efficacy of tigecycline
was comparable to that of meropenem in a large
cohort of patients with complicated IAI.[75] A
drawback, however, is that a pooled analysis
of 13 clinical trials for both approved and un-
approved indications for tigecycline (including
one trial on complicated IAI), demonstrated an
increased risk of death among patients receiving
tigecycline compared with patients receiving
comparator antibacterials (adjusted risk differ-
ence for all-cause mortality 0.6%, 95% CI 0.1,
1.2). This observation led to a recommendation
against the use of tigecycline in severe infec-
tions.[76] Following this FDA drug safety com-
munication, we do not recommend tigecycline in
patients with IAI presenting with septic shock
(tables I and II).
Tigecycline dosing is 50mg twice daily after a
100mg loading dose. It is a valuable option for
patients with penicillin allergy.
5. Directed Therapy
Once the result of cultures obtained during
surgery or after percutaneous drainage are avail-
able, de-escalation of antimicrobial therapy can
be considered when broad-spectrum agents have
been used as empirical therapy, most notably in
patients with severe community-acquired disease.
It should be remembered that anaerobes are more
difficult to culture and that often only the most
abundant micro-organisms are documented. As
most complicated IAI are polymicrobial in nature,
antimicrobial regimens used in a de-escalation
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strategy should also cover the full spectrum of
aerobic and anaerobic micro-organisms, not only
the micro-organisms that have been identified.
The only exception to this rule may be patients
with primary peritonitis, or selected patients with
postoperative abscesses with only one pathogen
identified on direct examination and culture.
6. Duration of Antimicrobial Therapy
for IAI
The duration of antimicrobial therapy should
ideally be defined from the start of the treatment.
In case of complicated IAI with prompt surgical
intervention and adequate source control, anti-
microbial therapy is generally recommended to
continue for 5–7 days, but shorter courses have
been proposed, most often based on the extent of
the infection and clinical response of the patient
to the treatment.[77] Yet, strong evidence to sup-
port such shorter courses remains scarce, espe-
cially for more severe cases. The largest body of
evidence is on the duration of antimicrobials in
children with acute appendicitis, where 3 days
of antimicrobials seems sufficient.[78] A recent
study found that adult patients with community-
acquired localized peritonitis of mild to moderate
severity who were treated for 3 days had similar
outcomes to patients treated for 5–10 days.[79]
Besides this study, the proposed duration of
antimicrobial therapy in IAI is largely based on
expert opinion. Table V summarizes the pro-
posed duration of antimicrobial therapy in IAI
according to the primary source of infection.[80]
In patients who require (repetitive) reoperation
because of failed source control, the operation in
which the source is definitely controlled should be
regarded as the index operation from which the
duration of therapy is calculated. In selected
patients, prolonged antimicrobial therapy may be
necessary, especially when source control is dif-
ficult or impossible to obtain.
7. Conclusion
We proposed an alternative classification of
IAI based on (i) anatomical disruption; (ii) severity
of disease expression; and (iii) either community-
acquired/early-onset healthcare-associated origin,
or late-onset healthcare-associated origin and/or
Table V. Duration of antimicrobial therapy according to primary site of infection[80]
Infection site Clinical context Duration of therapy
Abscess Exclusive liver or spleen abscesses 3–7 days after surgery or drainage







Ascending cholangitis No device
Device
Up to 24 hours after drainage
7 days in moderate to severe cases
Prolonged therapy if case of liver abscess












Gastro-duodenal perforation Time to intervention
 <24 hours
 >24 hours
 Peri-operative prophylaxis only
 3–7 days
Pancreatitis Proven infection or after 10 days of multiple
organ dysfunction
3–7 days
Peritonitis/anastomotic leakage Localized or generalized 3–7 days
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recent antimicrobial exposure. All possible com-
binations according to these three components
are summarized in a grid. The grid allows physi-
cians to select the most convenient empirical
antimicrobial regimen according to the clinical
situation. More precisely, it advises on the necessity
of covering P. aeruginosa or resistant Gram-
negative bacteria, enterococci and yeasts, albeit
that local patterns of microbial ecology should
also always be taken into account. In recent
years, some newer agents such as doripenem,
moxifloxacin and tigecycline have been added to
the antibacterial armamentarium for IAI. While
moxifloxacin and tigecycline can be used as first-
line single-agent therapy, doripenem can be used
when Pseudomonas and or resistant Gram-
negative pathogens are a concern. In patients in
whom the source can be adequately controlled,
antimicrobial therapy should be restricted to a
short course, generally 3–7 days after surgery.
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